Business Wire

RAPYD

Share
REPORT: Nearly 70% of Europeans Prefer Direct Bank Transfers As Top Preferred Method to Get Paid, According to Rapyd

Nearly seven out of 10 (67%) Europeans demand direct bank transfers as their most preferred method to be paid, indicating the growing need for businesses to provide fast and secure payments in consumers’ preferred payout methods.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220922005160/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Source: Rapyd’s 2022 European eCommerce and Payment Methods report (Graphic: Business Wire)

That’s according to a new report released by Rapyd, the leading fintech-as-a-service partner, after conducting research to understand consumer choices, considerations and preferences in nine European countries; including data on how consumers prefer to pay and receive payments.

Rapyd’s European State of Disbursements report finds that access to, and interest in, financial technology apps is very high among consumers in the nine European markets surveyed. Europeans are embracing financial services apps for everything from banking, everyday spending and managing their investments. The findings show that 74% of European consumers use a mobile banking app, 50% use an eWallet app, 50% use a credit or debit card app, approximately one in six (16%) use an investment fund app and approximately one in eight (12%) use a personal financial management app.

Rapyd’s European eCommerce and Payment Methods report also indicates that Europeans increasingly rely on phones for payments, financial management and eCommerce. Over half (52%) of Europeans report purchasing clothes online via mobile over the past three months, compared to 46% via laptop. Furthermore, the overwhelming majority of Europeans who purchased takeaway over the last 3 months did so via mobile (70%) compared to laptop (28%).

Rapyd’s State of Disbursements report also noted that Europeans are early adopters of fintech, prioritizing data security and lower costs when receiving payments. Only 16% are hesitant or lagging in the adoption of fintech. The data shows that 82% rank keeping their personal information secure as the most important feature for payouts, and over 70% of respondents do not want to pay any transaction fees.

The report further analyzes and compares each market’s attitudes towards fintech adoption. Interestingly, Spain had the highest number of early adopters or consumers more likely to be open to new fintech solutions (27%), followed by Iceland (22%) and Germany (20%). On the other hand, Denmark (54%), France (47%) and the UK (44%) had the highest number of consumers who identified as the ‘late majority.’ The analysis notes that these consumers are less likely to explore new financial technology, instead preferring to use the same platforms as family and friends.

Over half of global online transfers are currently made with local or alternative payment methods. This, coupled with the rapid growth of marketplaces and gig economy models, is driving the need for new payout technology in Europe, notes the report.

Rapyd also notes that with the roll-out of the Single Euro Payments Area (SEPA) continuing and the Nordics’ P27 payments initiative unfolding, real-time payments in Europe are here to stay, emphasizing the need to keep abreast of country-specific regulations. As such, the company is calling on businesses to ensure they have the infrastructure in place to guarantee reliable mass payouts driven by local preferences.

Commenting on the findings, Arik Shtilman, CEO of Rapyd, said:

“The companies that solve the technological challenges of disbursing funds in Europe will surge ahead of their competition. It’s critical that businesses responsible for online financial transactions have partners that can support them in delivering reliable payout and payment solutions, can keep on top of local regulations and can stay on top of consumer preferences. The businesses that invest in dynamic tech solutions to guarantee reliable mass payouts will no doubt enjoy stability and growth through better engagement, loyalty and beneficiary preference.

“Furthermore, given the growth of marketplaces and gig-economy platforms, working with partners that understand the evolving fintech space is key. Disbursing funds to a seller or worker is typically tied to individual sales on different platforms. This can be incredibly complex, as in many cases, the buyer, seller and platform provider are all in different locations. We recommend that businesses ensure local preferences are driving their payout strategy, with a particular focus on speed, security and choice, as these factors help drive greater use and adoption and build loyalty and trust.”

Rapyd’s 2022 European eCommerce and Payment Methods report and 2022 European State of Disbursements report are available here.

Notes to Editors:

Survey Methodology

Rapyd surveyed 4,286 adults (18+) in Denmark, France, Germany, Iceland, Italy, Netherlands, Sweden, Spain and the United Kingdom online in March and April 2022. All respondents made an online purchase in the previous month and were nationally representative across age and income scale.

About Rapyd

Rapyd lets you build bold. Liberate global commerce with all the tools your business needs to create payment, payout and fintech experiences everywhere. From Fortune 500s to ambitious business and technology upstarts, our payments network and powerful fintech platform make it easy to pay suppliers and get paid by customers—locally or internationally.

With offices worldwide, including Tel Aviv, Dubai, London, Iceland, San Francisco, Miami and Singapore, we know what it takes to make cross-border commerce as easy as being next door. Rapyd simplifies payments so you can focus on building your business.

Get the tools to grow globally at www.rapyd.net. Follow: Blog, Insta, LinkedIn, Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005160/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye